CA2738644A1 - Hepatitis c antibodies and uses thereof - Google Patents

Hepatitis c antibodies and uses thereof Download PDF

Info

Publication number
CA2738644A1
CA2738644A1 CA2738644A CA2738644A CA2738644A1 CA 2738644 A1 CA2738644 A1 CA 2738644A1 CA 2738644 A CA2738644 A CA 2738644A CA 2738644 A CA2738644 A CA 2738644A CA 2738644 A1 CA2738644 A1 CA 2738644A1
Authority
CA
Canada
Prior art keywords
hcv
antibody
antibodies
cbh
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2738644A
Other languages
English (en)
French (fr)
Inventor
Steven Foung
Zhen-Yong Keck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of CA2738644A1 publication Critical patent/CA2738644A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109Hepatitis C virus; Hepatitis G virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2738644A 2008-10-05 2008-10-05 Hepatitis c antibodies and uses thereof Abandoned CA2738644A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/078884 WO2010039154A1 (en) 2008-10-05 2008-10-05 Hepatitis c antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CA2738644A1 true CA2738644A1 (en) 2010-05-08

Family

ID=42073762

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2738644A Abandoned CA2738644A1 (en) 2008-10-05 2008-10-05 Hepatitis c antibodies and uses thereof

Country Status (12)

Country Link
US (1) US8858947B2 (cg-RX-API-DMAC7.html)
EP (1) EP2331573A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012504602A (cg-RX-API-DMAC7.html)
KR (1) KR20110061624A (cg-RX-API-DMAC7.html)
CN (1) CN102197050A (cg-RX-API-DMAC7.html)
AU (1) AU2008362482A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0823197A2 (cg-RX-API-DMAC7.html)
CA (1) CA2738644A1 (cg-RX-API-DMAC7.html)
EA (1) EA201170353A1 (cg-RX-API-DMAC7.html)
IL (1) IL212040A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011003613A (cg-RX-API-DMAC7.html)
WO (1) WO2010039154A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2495256A4 (en) * 2009-10-30 2013-09-25 Toray Industries ANTIBODIES HAVING INHIBITION ACTIVITY OF HEPATITIS C VIRUS (HCV) INFECTION AND USE THEREOF
WO2012107589A1 (en) * 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
JP6158171B2 (ja) 2011-05-02 2017-07-05 ザ・ジョンズ・ホプキンス・ユニバーシティ 合成c型肝炎ゲノム、並びに、その製造方法及びその使用
AU2013299986B2 (en) 2012-08-07 2018-05-17 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
CN103113458B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi34及其应用
CN103172705B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi16及其应用
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
US9902764B2 (en) 2014-02-11 2018-02-27 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
JPWO2015133467A1 (ja) * 2014-03-06 2017-04-06 株式会社シノテスト C型肝炎ウイルスのワクチン及び診断に用いるためのHBc/HCV E2ペプチドキメラタンパク質
CN104327170A (zh) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用
GB201415714D0 (en) * 2014-09-05 2014-10-22 Medical Res Council Antibodies and antigen binding fragments thereof
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
KR102640157B1 (ko) * 2016-03-22 2024-02-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 인간화 항-클라우딘-1 항체 및 이의 용도
CN107011435B (zh) * 2016-06-01 2019-02-12 苏州银河生物医药有限公司 抗丙型肝炎病毒的全人单克隆抗体8d6
EP4095156A1 (en) * 2021-05-28 2022-11-30 Universität zu Köln Neutralizing antibodies against hepatitis c virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1127170A4 (en) * 1998-11-05 2005-04-27 Univ Leland Stanford Junior HUMAN MONOCLONAL ANTIBODIES OF THE HEPATITIS C VIRUS (HCV) PAN
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
ES2529736T3 (es) * 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS

Also Published As

Publication number Publication date
BRPI0823197A2 (pt) 2015-06-23
CN102197050A (zh) 2011-09-21
EA201170353A1 (ru) 2011-12-30
MX2011003613A (es) 2011-08-03
EP2331573A1 (en) 2011-06-15
AU2008362482A1 (en) 2010-04-08
US20120039846A1 (en) 2012-02-16
KR20110061624A (ko) 2011-06-09
IL212040A0 (en) 2011-06-30
US8858947B2 (en) 2014-10-14
EP2331573A4 (en) 2012-09-05
WO2010039154A1 (en) 2010-04-08
JP2012504602A (ja) 2012-02-23

Similar Documents

Publication Publication Date Title
US8858947B2 (en) Hepatitis C antibodies and uses thereof
US7750123B2 (en) Antibodies against SARS-CoV and methods of use thereof
Tarr et al. An alpaca nanobody inhibits hepatitis C virus entry and cell‐to‐cell transmission
AU2008223561B2 (en) Human antibodies against hepatitis C virus (HCV) uses thereof
US20240050565A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
TW201815821A (zh) 抗茲卡病毒抗體及使用方法
EA034767B1 (ru) Человеческие антитела к белку f респираторного синцитиального вируса и способы их применения
EP1797125A2 (en) Prevention and treatment of hcv infection employing antibodies directed against conformational and linear epitopes
EP4282880A1 (en) Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof
CN102143975B (zh) 特异性配体在msrv相关疾病中的治疗用途
WO2007044695A2 (en) ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
WO2011092593A2 (en) Hiv-1 neutralizing antibodies and uses thereof
JP2012513457A (ja) Hcv感染の治療的処置および予防のための医薬としての抗hcvモノクローナル抗体
CN1768078B (zh) 针对丙型肝炎病毒e1e2复合体的抗体、hcv颗粒的组合物和药物组合物
US20100104555A1 (en) HCV neutralizing epitopes
US9884109B2 (en) Compositions and methods
JP2000509966A (ja) C型肝炎ウイルス(hcv)e2抗原に特異的なヒトモノクローナル抗体
US20030180284A1 (en) Prevention and treatment of HCV infection employing antibodies directed against conformational and linear epitopes
WO2010047829A1 (en) Mutant hepatitis c virus e2 polypeptides for hcv treatment
US9751931B2 (en) Hepatitis C virus neutralizing antibodies and methods
HK1201451B (zh) 组合物及其制备方法
AU2013251185A1 (en) Human antibodies against hepatitis C virus (HCV) and uses thereof
HK1233537B (en) Novel full spectrum anti-dengue antibody
HK1233537A1 (en) Novel full spectrum anti-dengue antibody
AU2012254920A1 (en) Improvements in or relating to treatment and prevention of viral infections

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20131007